Timothy Mark Dyer, Chief Executive Officer and Director of Addex Therapeutics Ltd. (NASDAQ:ADXN), filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.

Key Highlights

  • Transaction date: November 11, 2026, with 18,857,075 stock options (right to buy) acquired by Timothy Mark Dyer.
  • Exercise price: $0.026 per option, converted from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026.
  • Price paid: $0 for the derivative securities at time of grant.
  • Post-transaction holdings: Dyer beneficially owns 22,226,871 derivative securities (stock options) directly following the reported transaction.
  • Vesting schedule: Options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026.
  • Expiration date: November 10, 2036.
  • Underlying security: Each stock option grants the right to purchase one ADXN share listed on SIX Swiss Exchange.

Details of Timothy Mark Dyer's Stock Option Grant at Addex Therapeutics

According to the filing, Timothy Mark Dyer, who serves as both Chief Executive Officer and Director of Addex Therapeutics Ltd., reported the acquisition of 18,857,075 stock options (right to buy) with a transaction code of "A" (acquired) on November 11, 2026. The options carry an exercise price of $0.026, which the filing states reflects a conversion from CHF to USD at a rate of $1.1995 per CHF 1.00 as of November 11, 2026. The price of the derivative security at the time of grant is reported as $0.

The filing discloses that the options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026, and expire on November 10, 2036. Each stock option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange. The underlying security is identified as Common Stock, with 18,857,075 shares underlying the reported options.

Following the reported transaction, the filing states that Dyer directly beneficially owns 22,226,871 derivative securities. No non-derivative securities transactions were reported in Table I of the filing. The Form 4 was signed by Timothy Mark Dyer and dated November 13, 2026. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934 and covers one reporting person.

What Was Disclosed

Addex Therapeutics Ltd. CEO and Director Timothy Mark Dyer disclosed the acquisition of 18,857,075 stock options on November 11, 2026, at an exercise price of $0.026, with options vesting monthly over four years and expiring November 10, 2036.